Market reactionShares rose 12% on Nov 4.
Liquidia Corporation is a commercial-stage company selling YUTREPIA, an inhaled dry-powder treprostinil approved for pulmonary arterial hypertension (PAH), and developing L606, a twice-daily nebulized treprostinil.
Liquidia's case rests on YUTREPIA, an inhaled dry-powder treprostinil for pulmonary arterial hypertension, with preliminary Q3 2026 net sales of $222.7 million, up from $170.4 million in Q2. On October 13 Liquidia settled all litigation with United Therapeutics, agreeing to remove PH-ILD from YUTREPIA's label while it stays available in PAH. The settlement costs $380.7 million, which Liquidia expects to pay from $396.1 million in cash and YUTREPIA sales without new financing.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: YUTREPIA keeps growing in PAH after losing PH-ILD
How much do PAH sales carry YUTREPIA after the PH-ILD label is removed?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Liquidia settled all litigation with United Therapeutics: YUTREPIA stays on the market in PAH, the PH-ILD label goes, and $380.7 million is due
YUTREPIA's commercial ramp is real, but a patent ruling now threatens its PH-ILD label — appeal outcome determines whether the growth story holds
Profitable one year post-launch, YUTREPIA's commercial trajectory is the thesis — SSc-RP expansion is the upside option if Phase 2a data hold
YUTREPIA's commercial ramp is the thesis — sustaining market share against established prostacyclin alternatives and emerging inhaled competitors determines the outcome
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung and respiratory diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.